TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36052175
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (ST) high volume (3 sets per exercise) + photobiomodulation therapy (PBMt)
Study: 36052175
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (ST) low volume (1 set per exercise) + photobiomodulation therapy (PBMt)
Study: 34169551
Drug: Adjunct use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct use of deproteinized bovine bone mineral (DBBM) and native bilayer collagen membrane (NBCM)
Study: 35987208
Drug: Point-of-care viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care viral load testing every 3 months, targeted drug resistance mutation testing, and clinical decision support.
Study: 35987208
Drug: Targeted drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted drug resistance mutation testing in intervention participants.
Study: 33986070
Drug: Short duration
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short duration treatment strategy (antibiotics may be stopped as early as day 3 if respiratory cultures are negative, and day 5 if positive)
Study: 33986070
Drug: Standard-of-care duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care duration arm (antibiotics for at least 8 days)
Study: 33986070
Drug: Short duration
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short duration treatment strategy
Study: 35587457
Drug: Weekly intramuscular
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intramuscular (IM) 17 hydroxyprogesterone (17‐OHP)
Study: 36111381
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of DIM (300 mg of DIM-BR®) daily for 30 days
Study: 35431172
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg monthly for 52 weeks
Study: 34544808
Drug: 6-month salsa
Normalized name: CISTANCHE SALSA STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month salsa dance training intervention, 2 weekly 1-hour sessions
Study: 32186977
Drug: Beef protein
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef protein supplementation (BEEF), 25 g daily for 8 weeks
Study: 32186977
Drug: Isoenergetic carbohydrates
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic carbohydrates (CHO) supplement
Study: 33211769
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy with negative pressure of 400 mmHg for 15 minutes, twice a week, for 4 weeks
Study: 34176448
Drug: Extended-Release Injectable
Normalized name: Exenatide for Extended-Release Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-Release Injectable Naltrexone (XR-NTX)
Study: 34854982
Drug: Intradialytic cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic cycling (IDC), 30 min of moderate intensity (RPE 12-14), thrice weekly for 6 months
Study: 36241492
Drug: Malkia Klabu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malkia Klabu intervention (girl-friendly drug shops)
Study: 35768875
Drug: Interactive text
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive text messaging intervention (iTAB-CV) with daily texts for 2 months, followed by either high or low booster texts for an additional 2 months
Study: 35768875
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of medication taking, mood, and home blood pressure
Study: 35672892
Drug: Yinhua Miyanling
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Yinhua Miyanling tablets (YMT) 2 g qid orally
Study: 35672892
Drug: Placebo (dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dummy YMT) 2 g qid orally
Study: 32993256
Drug: Butorphanol patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol patient‐controlled intravenous analgesia (0.15 mg/kg)
Study: 32993256
Drug: Sufentanil patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil patient‐controlled intravenous analgesia (1.5 μg/kg)
Study: 32993256
Drug: Butorphanol patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol patient‐controlled intravenous analgesia
Study: 35466481
Drug: Lamisil AT
Normalized name: LamISIL AT
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamisil AT 1% spray
Study: 33094868
Drug: Systemic family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic family treatment
Study: 34780095
Drug: NAL‐ER162 (162
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAL‐ER162 (162 mg twice daily)
Study: 34780095
Drug: NAL‐ER81 (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAL‐ER81 (81 mg twice daily)
Study: 32933995
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI) use
Study: 35412366
Drug: Leptomeningeal metastatic
Normalized name: Kiss-1 metastasis suppressor
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptomeningeal metastatic dissemination before treatment
Study: 32891738
Drug: D-index-guided early
Normalized name: MAGNI-GUIDE (B-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-index-guided early antifungal therapy (DET) using micafungin
Study: 32891738
Drug: Empirical antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antifungal therapy (EAT) using micafungin
Study: 35857327
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message intervention stating a vaccine had been reserved, with scheduled vaccination date and follow-up reminders.
Study: 34563211
Drug: Anakinra (Kineret®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (Kineret®), a human recombinant interleukin‐1 receptor antagonist (rhIL1ra)
Study: 34294072
Drug: Zinc chloride
Normalized name: Zinc Chloride
DrugBank: Zinc chloride (DB14533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc chloride mouthwash (7.5 ml, rinsed every 8 hours for 2 minutes)
Study: 32951067
Drug: 12.5 g
Normalized name: glycerin 12.5 GM per 20.4 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 g Litesse®Ultra (PDX)
Study: 36215323
Drug: Monthly sulfadoxine/pyrimethamine‐amodiaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine/pyrimethamine‐amodiaquine (SP‐AQ)
Study: 34121333
Drug: Lower-sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower-sodium oxybate (LXB) 4.5 g
Study: 34121333
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) 4.5 g
Study: 35550405
Drug: Standard arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm (standard radiation therapy plan without 3He MRI)
Study: 35302931
Drug: Daily Model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Model (DM)
Study: 35302931
Drug: Weekly Model
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Model (WM)
Study: 32398047
Drug: Canrenone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenone (200 mg intravenously within 2-3 min)
Study: 33147327
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 g single dose
Study: 35483886
Drug: OB (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: OB (40 mg three times a day)
Study: 34973304
Drug: 0.5% bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine, 30 mL to 14 mL
Study: 34973304
Drug: 0.5% bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine, 14 mL
Study: 34973304
Drug: 0.5% bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine, 30 mL
Study: 34973304
Drug: 0.5% bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine, 12 mL
Study: 35759124
Drug: PDS 10
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PDS 10 mg/ml
Study: 35759124
Drug: PDS 40
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PDS 40 mg/ml
Study: 35759124
Drug: PDS 100
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PDS 100 mg/ml
Study: 35427803
Drug: Monthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly ranibizumab 0.5 mg
Study: 36321459
Drug: Sacubitril/valsartan (97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (97/103 mg twice daily)
Study: 34526064
Drug: Ketamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusions (six total)
Study: 34526064
Drug: Ketamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusions (six total) in pain group
Study: 34526064
Drug: Ketamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusions (six total) in non-pain group
Study: 33565042
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available treatment (BAT)
Study: 33167920
Drug: TS-141 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-141 30 mg once a day
Study: 33167920
Drug: TS-141 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-141 60 mg once a day
Study: 33167920
Drug: TS-141 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-141 120 mg (60 mg twice a day)
Study: 35552788
Drug: 8-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-day antibiotic treatment
Study: 35552788
Drug: 15-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-day antibiotic treatment
Study: 34270458
Drug: COVID-19 vaccines
Normalized name: Covid-19 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccines (specific vaccines and dosages not mentioned)
Study: 35079115
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg twice daily for 8 weeks, followed by bicalutamide 50 mg/day
Study: 35079115
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg/day alone (after 8 weeks of observation)
Study: 35079115
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and bicalutamide
Study: 32770693
Drug: Single-plane MFU-V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-plane MFU-V treatment (4 MHz/4.5 mm transducer)
Study: 32770693
Drug: Dual-plane MFU-V
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-plane MFU-V treatment (4 MHz/4.5 mm and 7 MHz/3.0 mm transducer)
Study: 35644803
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) with flow: 50 L/min and FIO2 of 1.0
Study: 35644803
Drug: Ordinary supplemental
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary supplemental oxygen via a nasal cannula (flow: 6 L/min)
Study: 36111149
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment
Study: 36351727
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (ciprofloxacin and metronidazole) added to surgical drainage of perianal abscess
Study: 34085779
Drug: subcutaneous Ig
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous Ig (IgPro20; Hizentra®)
Study: 32785245
Drug: Acceptance Facilitating
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance Facilitating Intervention (AFI) - short video showing an example of blended therapy
Study: 34687909
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment approaches (control group)
Study: 34144145
Drug: Yoga (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga (12 weekly sessions)
Study: 36047065
Drug: Taurine 3
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine 3 g, twice/day, orally for 12 weeks
Study: 32440731
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (1.32×10^11 CFU live bacteria including Lactobacillus acidophilus, Lactobacillus rhamnosus GG, Bifidobacterium animalis, and Bifidobacterium longum daily)
Study: 32400356
Drug: Praziquantel mass
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel mass drug administration (MDA)
Study: 32598751
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day)
Study: 32598751
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy with bismuth (Omeprazole 20 mg 2 times a day, Tetracycline 500 mg 4 times a day, Metronidazole 500 mg 3 times a day, Bismuth subcitrate potassium 120 mg 4 times a day)
Study: 32598751
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy without bismuth (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day, Metronidazole 500 mg 2 times a day)
Study: 35187781
Drug: BBL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBL treatment and intradermal injection of BTX
Study: 35187781
Drug: BBL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBL treatment and intradermal injection of normal saline
Study: 33857940
Drug: Endotoxin Adsorbent
Normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin Adsorbent (EA) therapy
Study: 33111988
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate 2.5 mg chip (ChxC) as an adjunctive treatment to subgingival debridement
Study: 33111988
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate 2.5 mg chip (ChxC)
Study: 32379217
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg E4
Study: 32907576
Drug: Navafenterol (50-2100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navafenterol (50-2100 μg)
Study: 35043571
Drug: Alginate dressings
Normalized name: Restore Calcium Alginate Dressings 4x4.75"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate dressings with silver and high-G cellulose
Study: 35997105
Drug: 4 units
Normalized name: Afrezza, 4 units inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 units of cryoprecipitate added to routine treatments
Study: 35997105
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments without cryoprecipitate
Study: 32531432
Drug: Enterovirus 71
Normalized name: ENTEROVIRUS 71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterovirus 71 (EV71) vaccine
Study: 32077057
Drug: Intranasal glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal glulisine
Study: 34696733
Drug: Ultrasound-guided psoas
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided psoas compartment block (PCB) with bupivacaine 0.125% 6-8 ml/h
Study: 32404742
Drug: Probiotics supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics supplemented with 100 mg bovine lactoferrin (bLf)
Study: 35817738
Drug: HIFU and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU and ultrasound-guided percutaneous anhydrous ethanol injection with oxytocin
Study: 35817738
Drug: HIFU and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU and ultrasound-guided percutaneous anhydrous ethanol injection (Control)
Study: 33906853
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg two times per day for 16 weeks
Study: 36154509
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD2, 5 mg/ml)
Study: 36154509
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD1, 2 mg/ml)
Study: 34425422
Drug: Self-management training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management training program (delivered by physical therapy doctoral students, 6-week duration)
Study: 35775676
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine injection
Study: 35775676
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bupivacaine injection)
Study: 34849989
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 6 months for 12 months
Study: 34535967
Drug: Denosumab 180
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 180 mg every 6 months for 12 months
Study: 36124755
Drug: Intensive Language‐Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Language‐Action Therapy combined with standard care
Study: 39358667
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg risankizumab
Study: 35451681
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) syndrome differentiation
Study: 34164939
Drug: Various mental
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various mental health interventions including Cognitive Behaviour Therapy, psychosocial approaches, group-based and family strengthening interventions, economic empowerment combined with family strengthening, group-based mindfulness, and community interventions.
Study: 34164939
Drug: Traditional mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional mental health treatments and psychosocial interventions.
Study: 33482888
Drug: TESI combined
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TESI combined with levobupivacaine added to oral pain medication
Study: 33482888
Drug: Oral pain
Normalized name: Oral Pain Relief
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pain medication alone
Study: 33482888
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural injection with levobupivacaine and saline solution added to oral pain medication
Study: 33482888
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral pain medication alone)
Study: 35435194
Drug: Dexamethasone combined
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone combined with oxybuprocaine hydrochloride gel (G group)
Study: 35507446
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) continuation
Study: 35507446
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) withdrawal
Study: 34109590
Drug: Rehabilitation training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation training on the basis of routine drug therapy
Study: 36191597
Drug: Polycaprolactone injection
Normalized name: caprolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycaprolactone injection
Study: 36191597
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate gel injection
Study: 33516674
Drug: Cognition-enhancing medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognition-enhancing medications
Study: 36031273
Drug: Non-punitive performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-punitive performance feedback via weekly text messages about driving score and rank
Study: 32031757
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for conversion disorder/functional neurological disorder (CD/FND)
Study: 32031757
Drug: Comorbid depression
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comorbid depression treatment
Study: 36253729
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume ESPB with 20 ml 0.25% bupivacaine
Study: 36253729
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume ESPB with 40 ml 0.125% bupivacaine